Open AccessEicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
Author(s) -
Elajami Tarec K.,
Alfaddagh Abdulhamied,
Lakshminarayan Dharshan,
Soliman Michael,
Chandnani Madhuri,
Welty Francine K.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.004740
Subject(s) - medicine , albuminuria , angiotensin receptor , eicosapentaenoic acid , diabetes mellitus , endocrinology , docosahexaenoic acid , angiotensin converting enzyme , coronary artery disease , type 2 diabetes mellitus , creatinine , angiotensin ii , blood pressure , polyunsaturated fatty acid , fatty acid , chemistry , organic chemistry
Albuminuria is a marker of inflammation and an independent predictor of cardiovascular morbidity and mortality. The current study evaluated whether eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation attenuates progression of albuminuria in subjects with coronary artery disease.